In the complex framework of spinal cord injury, a yet unmet clinical need, we are pleased to announce that our SpinoSave® therapy was granted the orphan medicinal product designation by the European Commission, under nr. EU/3/24/2909.
We will now start our preparatory journey towards clinical investigations!
Read our press release and follow us along our journey to make paralysis a thing of the past!